Xeris Pharmaceuticals Inc (XERS) Stock Price, Quote & News - Mboum

Company Profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatmen...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 844 445 5704

Website: www.xerispharma.com

Address:

1375 West Fulton Street, Suite 1300, Chicago, United States

Meldemel Aug. 19 at 5:56 PM

$XERS Moderna will have nothing in this baby once we see September 9.

0 · Reply

Meldemel Aug. 19 at 5:54 PM

$XERS cannot be held down. 22 and beyond inevitable.

0 · Reply

n9zro Aug. 19 at 2:20 PM

$XERS Come on and Breakout !

0 · Reply

RM03 Aug. 19 at 1:56 PM

$XERS - let's push past this $9 speed bump and floor it!

0 · Reply

Invest0r_Gadget Aug. 19 at 1:49 PM

$XERS Sept 9 Levo is coming! $20.26

0 · Reply

Northwoodspeculator Aug. 19 at 1:42 PM

0 · Reply

gimoozaabi Aug. 19 at 1:41 PM

$XERS let’s get this done already. Crush that $9 and onto September 9 for clear path forward.

0 · Reply

durocali Aug. 19 at 1:31 PM

$XERS holding since $1.88 in 2021 and NO reason to sell anytime soon. shorted share total now under 10m for first time since 2024 as there has been slow-steady covering. $200M in new institution inflows in q2 alone with less than 160k sold in same period. $9 and up inevitable... GL longs..

0 · Reply

LorriPurdy207 Aug. 19 at 9:13 AM

$LOW $NKE $XERS $PDI Lowe's benefits from home-improvement and housing demand, Nike remains tied to global consumer spending, Xeris advances specialty pharmaceutical products, and PDI provides income-oriented exposure. I'm watching housing activity, retail sales, prescription growth, yields, and margins.

0 · Reply

Alon_R Aug. 19 at 8:12 AM

1 · Reply

Latest News on XERS

Xeris Biopharma Holdings Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 13 days ago

Xeris Biopharma Holdings Earnings Call Transcript: Q2 2026

Xeris Biopharma Holdings Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 13 days ago

Xeris Biopharma Holdings Earnings release: Q2 2026

Xeris Biopharma Holdings Quarterly report: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 13 days ago

Xeris Biopharma Holdings Quarterly report: Q2 2026

Xeris Biopharma tightens FY26 revnue view $385M-$390M, consensus $385.94M

2026-08-06T11:17:36.000Z - 13 days ago

Xeris Biopharma tightens FY26 revnue view $385M-$390M, consensus $385.94M

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Aug 6, 2026, 7:00 AM EDT - 13 days ago

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Jul 23, 2026, 7:30 AM EDT - 27 days ago

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jul 2, 2026, 10:40 PM EDT - 6 weeks ago

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jul 2, 2026, 4:05 PM EDT - 6 weeks ago

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Biopharma appoints CEO John Shannon as chair of the board

2026-06-30T11:05:52.000Z - 7 weeks ago

Xeris Biopharma appoints CEO John Shannon as chair of the board

Xeris Announces Updates to Its Board of Directors

Jun 30, 2026, 7:00 AM EDT - 7 weeks ago

Xeris Announces Updates to Its Board of Directors

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®

Jun 11, 2026, 4:39 PM EDT - 2 months ago

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®

Xeris Biopharma announces private exchange of convertible notes

2026-06-11T11:11:41.000Z - 2 months ago

Xeris Biopharma announces private exchange of convertible notes

Xeris Biopharma Announces Private Exchange of Convertible Notes

Jun 11, 2026, 7:00 AM EDT - 2 months ago

Xeris Biopharma Announces Private Exchange of Convertible Notes

Xeris Biopharma Holdings Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 4:20 PM EDT - 2 months ago

Xeris Biopharma Holdings Transcript: Jefferies Global Healthcare Conference 2026

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2026

Xeris Biopharma Holdings Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Xeris Biopharma Holdings Earnings release: Q1 2026

Xeris Biopharma Holdings Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Xeris Biopharma Holdings Quarterly report: Q1 2026

Xeris Biopharma Reports First Quarter 2026 Financial Results

May 7, 2026, 7:00 AM EDT - 3 months ago

Xeris Biopharma Reports First Quarter 2026 Financial Results

Xeris Biopharma Holdings Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Xeris Biopharma Holdings Proxy statement: Proxy filing

Xeris Biopharma Holdings Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Xeris Biopharma Holdings Proxy statement: Proxy filing

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 23, 2026, 7:30 AM EDT - 4 months ago

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Apr 3, 2026, 4:15 PM EDT - 4 months ago

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 11:30 AM EDT - 5 months ago

Xeris Biopharma Holdings Transcript: Barclays 28th Annual Global Healthcare Conference

Xeris Biopharma Holdings Slides: Corporate presentation

Mar 4, 2026, 6:00 AM EST - 6 months ago

Xeris Biopharma Holdings Slides: Corporate presentation

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:30 AM EST - 6 months ago

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2025

Xeris Biopharma Holdings Annual report: Q4 2025

Mar 2, 2026, 8:30 AM EST - 6 months ago

Xeris Biopharma Holdings Annual report: Q4 2025

Xeris Biopharma Holdings Earnings release: Q4 2025

Mar 2, 2026, 8:30 AM EST - 6 months ago

Xeris Biopharma Holdings Earnings release: Q4 2025

Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

Mar 2, 2026, 7:00 AM EST - 6 months ago

Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

Xeris Biopharma subsidiaries file Recorlev patent infringement lawsuit

2026-02-26T23:00:23.000Z - 6 months ago

Xeris Biopharma subsidiaries file Recorlev patent infringement lawsuit

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

Feb 26, 2026, 5:55 PM EST - 6 months ago

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

Feb 17, 2026, 7:30 AM EST - 6 months ago

Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

Jan 8, 2026, 7:00 AM EST - 7 months ago

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 2, 2026, 4:15 PM EST - 8 months ago

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma initiated with an Overweight at Barclays

2025-12-08T21:30:17.000Z - 9 months ago

Xeris Biopharma initiated with an Overweight at Barclays

Xeris Biopharma Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 12:30 PM EST - 9 months ago

Xeris Biopharma Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference

Xeris Biopharma issued notice of allowance from USPTO for XP-8121

2025-12-01T12:10:58.000Z - 9 months ago

Xeris Biopharma issued notice of allowance from USPTO for XP-8121

Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

Dec 1, 2025, 7:00 AM EST - 9 months ago

Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application

Xeris Biopharma price target raised to $8 from $6 at Piper Sandler

2025-11-07T11:55:51.000Z - 10 months ago

Xeris Biopharma price target raised to $8 from $6 at Piper Sandler

Xeris Biopharma Holdings Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Xeris Biopharma Holdings Earnings Call Transcript: Q3 2025

Xeris Biopharma Holdings Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Xeris Biopharma Holdings Quarterly report: Q3 2025

Xeris Biopharma Holdings Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Xeris Biopharma Holdings Earnings release: Q3 2025

Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

Xeris Biopharma price target raised to $18 from $8 at Oppenheimer

2025-10-29T12:15:22.000Z - 10 months ago

Xeris Biopharma price target raised to $18 from $8 at Oppenheimer

Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 23, 2025, 7:30 AM EDT - 10 months ago

Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 4:15 PM EDT - 11 months ago

Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xeris Biopharma Holdings Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 10:00 AM EDT - 1 year ago

Xeris Biopharma Holdings Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Xeris Biopharma announces Orange Book listing of U.S. patent for Recorlev

2025-08-25T11:05:21.000Z - 1 year ago

Xeris Biopharma announces Orange Book listing of U.S. patent for Recorlev

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

Aug 25, 2025, 7:00 AM EDT - 1 year ago

Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®

Xeris Biopharma assumed with a Buy at H.C. Wainwright

2025-08-12T10:10:13.000Z - 1 year ago

Xeris Biopharma assumed with a Buy at H.C. Wainwright

Xeris Biopharma price target raised to $8 from $7 at Oppenheimer

2025-08-08T13:05:44.000Z - 1 year ago

Xeris Biopharma price target raised to $8 from $7 at Oppenheimer

Xeris Biopharma Holdings Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Xeris Biopharma Holdings Earnings Call Transcript: Q2 2025

Xeris Biopharma Holdings Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Xeris Biopharma Holdings Quarterly report: Q2 2025

Xeris Biopharma Holdings Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Xeris Biopharma Holdings Earnings release: Q2 2025

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025

Xeris Biopharma Holdings Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 1:25 PM EDT - 1 year ago

Xeris Biopharma Holdings Transcript: Jefferies Global Healthcare Conference 2025

Xeris Biopharma Holdings Transcript: Investor Day 2025

Jun 3, 2025, 10:00 AM EDT - 1 year ago

Xeris Biopharma Holdings Transcript: Investor Day 2025

Xeris Biopharma Holdings Slides: FY 2025

Jun 3, 2025, 10:00 AM EDT - 1 year ago

Xeris Biopharma Holdings Slides: FY 2025

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

Jun 3, 2025, 7:30 AM EDT - 1 year ago

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

Xeris Announces Details for Analyst & Investor Day

May 20, 2025, 7:30 AM EDT - 1 year ago

Xeris Announces Details for Analyst & Investor Day

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2025

Xeris Biopharma Holdings Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Xeris Biopharma Holdings Quarterly report: Q1 2025

Xeris Biopharma Holdings Earnings release: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Xeris Biopharma Holdings Earnings release: Q1 2025

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 1 year ago

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Xeris Biopharma Holdings Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Xeris Biopharma Holdings Proxy statement: Proxy Filing

Xeris Biopharma Holdings Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Xeris Biopharma Holdings Proxy statement: Proxy Filing

Xeris Announces Changes to Its Board of Directors

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Xeris Announces Changes to Its Board of Directors

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

Xeris Biopharma Holdings Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 8:40 AM EDT - 1 year ago

Xeris Biopharma Holdings Transcript: Leerink Global Healthcare Conference 2025

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2024

Xeris Biopharma Holdings Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Annual report: Q4 2024

Xeris Biopharma Holdings Earnings release: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Earnings release: Q4 2024

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Mar 6, 2025, 7:00 AM EST - 1 year ago

Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Xeris Biopharma Holdings Registration statement: Registration Filing

Mar 6, 2025, 7:00 AM EST - 1 year ago

Xeris Biopharma Holdings Registration statement: Registration Filing

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Feb 27, 2025, 7:00 AM EST - 1 year ago

Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Feb 24, 2025, 8:00 AM EST - 1 year ago

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Xeris Biopharma Holdings Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 12, 2025, 1:20 PM EST - 1 year ago

Xeris Biopharma Holdings Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Xeris to Participate in Upcoming Investor Conferences

Feb 5, 2025, 8:00 AM EST - 1 year ago

Xeris to Participate in Upcoming Investor Conferences

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Jan 21, 2025, 9:00 AM EST - 1 year ago

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Jan 10, 2025, 7:00 AM EST - 1 year ago

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Xeris Biopharma Holdings Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 1 year ago

Xeris Biopharma Holdings Transcript: Piper Sandler 36th Annual Healthcare Conference

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

Xeris Biopharma Holdings Earnings Call Transcript: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Earnings Call Transcript: Q3 2024

Xeris Biopharma Holdings Quarterly report: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Quarterly report: Q3 2024

Xeris Biopharma Holdings Earnings release: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Xeris Biopharma Holdings Earnings release: Q3 2024

Xeris Biopharma Reports Third Quarter 2024 Financial Results

Nov 8, 2024, 7:00 AM EST - 1 year ago

Xeris Biopharma Reports Third Quarter 2024 Financial Results

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

Xeris Biopharma Holdings Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 10, 2024, 3:30 PM EDT - 2 years ago

Xeris Biopharma Holdings Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Xeris Biopharma Holdings Slides: Corporate Presentation

Aug 12, 2024, 6:00 AM EDT - 2 years ago

Xeris Biopharma Holdings Slides: Corporate Presentation

Xeris Biopharma Holdings Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Earnings Call Transcript: Q2 2024

Xeris Biopharma Holdings Quarterly report: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Quarterly report: Q2 2024

Xeris Biopharma Holdings Earnings release: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Earnings release: Q2 2024

Xeris Biopharma Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Xeris Biopharma Reports Second Quarter 2024 Financial Results

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

Jul 25, 2024, 7:00 AM EDT - 2 years ago

Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024

Xeris Biopharma Announces CEO Succession Plan

Jul 8, 2024, 7:00 AM EDT - 2 years ago

Xeris Biopharma Announces CEO Succession Plan

Xeris Biopharma Holdings Transcript: Jefferies 2024 Global Healthcare Conference

Jun 6, 2024, 2:00 PM EDT - 2 years ago

Xeris Biopharma Holdings Transcript: Jefferies 2024 Global Healthcare Conference

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

May 30, 2024, 7:30 AM EDT - 2 years ago

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

Xeris to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 7:00 AM EDT - 2 years ago

Xeris to Participate in the Jefferies Global Healthcare Conference

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Earnings Call Transcript: Q1 2024

Xeris Biopharma Holdings Quarterly report: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Quarterly report: Q1 2024

Xeris Biopharma Holdings Earnings release: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Xeris Biopharma Holdings Earnings release: Q1 2024

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

May 9, 2024, 7:00 AM EDT - 2 years ago

Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

May 6, 2024, 7:00 AM EDT - 2 years ago

Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

May 2, 2024, 7:00 AM EDT - 2 years ago

Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024

Xeris Biopharma Holdings Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Xeris Biopharma Holdings Proxy statement: Proxy Filing

Xeris Biopharma Holdings Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Xeris Biopharma Holdings Proxy statement: Proxy Filing

Xeris Biopharma Holdings Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 9, 2024, 11:00 AM EDT - 2 years ago

Xeris Biopharma Holdings Transcript: 23rd Annual Needham Virtual Healthcare Conference

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Xeris Biopharma Holdings Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 11, 2024, 11:20 AM EDT - 2 years ago

Xeris Biopharma Holdings Transcript: Leerink Partners Global Biopharma Conference 2024

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

Xeris Biopharma Holdings Earnings Call Transcript: Q4 2023

Xeris Biopharma Holdings Annual report: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

Xeris Biopharma Holdings Annual report: Q4 2023

Xeris Biopharma Holdings Earnings release: Q4 2023

Mar 6, 2024, 8:30 AM EST - 2 years ago

Xeris Biopharma Holdings Earnings release: Q4 2023

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

Mar 6, 2024, 7:02 AM EST - 2 years ago

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

Mar 6, 2024, 7:00 AM EST - 2 years ago

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Feb 28, 2024, 7:00 AM EST - 2 years ago

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Meldemel Aug. 19 at 5:56 PM

$XERS Moderna will have nothing in this baby once we see September 9.

0 · Reply

Meldemel Aug. 19 at 5:54 PM

$XERS cannot be held down. 22 and beyond inevitable.

0 · Reply

n9zro Aug. 19 at 2:20 PM

$XERS Come on and Breakout !

0 · Reply

RM03 Aug. 19 at 1:56 PM

$XERS - let's push past this $9 speed bump and floor it!

0 · Reply

Invest0r_Gadget Aug. 19 at 1:49 PM

$XERS Sept 9 Levo is coming! $20.26

0 · Reply

Northwoodspeculator Aug. 19 at 1:42 PM

0 · Reply

gimoozaabi Aug. 19 at 1:41 PM

$XERS let’s get this done already. Crush that $9 and onto September 9 for clear path forward.

0 · Reply

durocali Aug. 19 at 1:31 PM

$XERS holding since $1.88 in 2021 and NO reason to sell anytime soon. shorted share total now under 10m for first time since 2024 as there has been slow-steady covering. $200M in new institution inflows in q2 alone with less than 160k sold in same period. $9 and up inevitable... GL longs..

0 · Reply

LorriPurdy207 Aug. 19 at 9:13 AM

$LOW $NKE $XERS $PDI Lowe's benefits from home-improvement and housing demand, Nike remains tied to global consumer spending, Xeris advances specialty pharmaceutical products, and PDI provides income-oriented exposure. I'm watching housing activity, retail sales, prescription growth, yields, and margins.

0 · Reply

Alon_R Aug. 19 at 8:12 AM

1 · Reply

Ithaca2018 Aug. 19 at 4:48 AM

$XERS Bregman brings it in, Cubs win!

0 · Reply

Ithaca2018 Aug. 19 at 1:55 AM

$XERS And our MVP opens on September 13th! Go Ravens! 🧜‍♀️

0 · Reply

Ithaca2018 Aug. 19 at 1:33 AM

$XERS Here we go! 🧜‍♀️ Wait, where is AC and Brodman? LOL!!!!!!

2 · Reply

LoneBroker Aug. 18 at 9:39 PM

$XERS $HPE $STRC

0 · Reply

Finwizard61 Aug. 18 at 9:32 PM

$XERS $10 on the way. Time to add more folks as breakout imminent.

1 · Reply

hashemtrade Aug. 18 at 8:24 PM

$XERS Strong princess. We are soon about to leave single digit territory.

0 · Reply

Ithaca2018 Aug. 18 at 8:01 PM

$XERS Break the news like AMLX did today and we get 65%++++++🧜‍♀️

1 · Reply

Ithaca2018 Aug. 18 at 7:58 PM

$XERS Just WOW!🧜‍♀️

0 · Reply

PatFB Aug. 18 at 7:40 PM

$XERS princess!

1 · Reply

Bullisch_150 Aug. 18 at 7:38 PM

$XERS beast modus, big deal or big buyout 9 September

0 · Reply

PatFB Aug. 18 at 7:28 PM

$XERS Strong like bull. 🐂

0 · Reply

Invest0r_Gadget Aug. 18 at 2:43 PM

$XERS Sept 9 Levo. Get your popcorn ready. More buyers/investors are coming!

0 · Reply